Shanghai Medicilon Past Earnings Performance
Past criteria checks 0/6
Shanghai Medicilon's earnings have been declining at an average annual rate of -15.2%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 20.2% per year.
Key information
-15.2%
Earnings growth rate
-15.1%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 20.2% |
| Return on equity | -11.8% |
| Net Margin | -28.1% |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How Shanghai Medicilon makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 984 | -277 | 245 | 98 |
| 30 Jun 24 | 1,015 | -270 | 253 | 109 |
| 31 Mar 24 | 1,174 | -172 | 262 | 119 |
| 31 Dec 23 | 1,366 | -33 | 264 | 122 |
| 30 Sep 23 | 1,602 | 175 | 226 | 132 |
| 30 Jun 23 | 1,788 | 342 | 228 | 133 |
| 31 Mar 23 | 1,754 | 363 | 239 | 128 |
| 31 Dec 22 | 1,659 | 338 | 228 | 123 |
| 30 Sep 22 | 1,621 | 379 | 220 | 109 |
| 30 Jun 22 | 1,425 | 332 | 189 | 96 |
| 31 Mar 22 | 1,309 | 314 | 153 | 86 |
| 31 Dec 21 | 1,167 | 282 | 141 | 78 |
| 30 Sep 21 | 1,019 | 236 | 129 | 71 |
| 30 Jun 21 | 891 | 196 | 118 | 59 |
| 31 Mar 21 | 775 | 159 | 104 | 52 |
| 31 Dec 20 | 666 | 129 | 92 | 45 |
| 30 Sep 20 | 569 | 95 | 81 | 39 |
| 30 Jun 20 | 511 | 86 | 75 | 35 |
| 31 Mar 20 | 467 | 70 | 74 | 31 |
| 31 Dec 19 | 449 | 67 | 70 | 27 |
| 30 Sep 19 | 407 | 64 | 61 | 23 |
| 31 Dec 18 | 325 | 61 | 46 | 16 |
| 31 Dec 17 | 249 | 42 | 36 | 10 |
| 31 Dec 16 | 232 | 43 | 28 | 9 |
| 31 Dec 15 | 164 | 26 | 39 | 0 |
| 31 Dec 14 | 109 | -3 | 34 | 0 |
Quality Earnings: 688202 is currently unprofitable.
Growing Profit Margin: 688202 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688202 is unprofitable, and losses have increased over the past 5 years at a rate of 15.2% per year.
Accelerating Growth: Unable to compare 688202's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688202 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-14.4%).
Return on Equity
High ROE: 688202 has a negative Return on Equity (-11.77%), as it is currently unprofitable.